Expired contract

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Details

Buyer: NHS England
Supplier(s): 38 suppliers
AVENTIS PHARMA LIMITED
Abbvie Ltd
Accord UK Ltd
Almirall
Amgen Ltd
Astra Zeneca UK Limited
Bayer Public Limited Company
Celltrion Healthcare United Kingdom Ltd
Chugai Pharma UK Ltd
CST Pharma Limited
Dr Reddy's Laboratories (UK) Ltd
Eli Lilly and Company Ltd
Galapagos Biotech Ltd
GEDEON RICHTER (UK) LIMITED
GLAXOSMITHKLINE UK LIMITED
Ipsen
Janssen Cilag Ltd
Kent Pharma Ltd
Merck Serono Limited
MERCK SHARP & DOHME (UK) LIMITED
Merz
Mylan
Napp Pharmaceuticals Ltd
Neon Healthcare Ltd
Novartis Pharmaceutical UK Ltd
Novo Nordisk Ltd
Organon Pharmaceuticals UK Ltd
Orifarm UK
Pfizer Liimted
Pharmacosmos UK Ltd
Ranbaxy (UK) Ltd
Roche Products Ltd
Sandoz
Swedish Orphan Biovitrum Ltd (Sobi UK Ltd)
Teva UK Ltd
Thornton and Ross
Vifor Pharma UK Ltd
Zentiva Pharma UK Ltd
Value: £688,010,000
Duration: 3 years
Topic: Pharmaceutical products
Published: 26 February 2024
Source: uk:contracts_finder

Tender description

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Timeline

Completed: Award published26 February 2024
Current notice
Completed: Award date1 March 2024
Completed: Contract expiry date31 August 2026

About the buyer

NHS England runs the NHS in England, and buys as a central healthcare organisation with its own team of procurement professionals. Every tender is advertised on Atamis, the NHS's single eCommercial system, and larger contracts appear on Find a Tender. Much of this procurement flows through framework agreements and the Crown Commercial Service. Clinical services are commissioned directly or through the Provider Selection Regime. Seven regional teams support the commissioning of healthcare services across the country. The central commercial function that develops procurement strategy for the whole NHS sits here.

UK health spending has nearly quadrupled to £241.8bn in 2024/25, £20bn up on the year before. £140.6bn of that went to procurement, the biggest sector of UK public spending and the fastest-growing.

Over the past 5 years, most of NHS England's contract awards have been in education and training, health and social work, and IT services.

Relevant CPV codes

33600000 · Pharmaceutical products

Decision makers

Connect with the people behind this procurement.

Job title	Phone number	Work email
Head of Procurement	+44 •••• ••••••	••••••••@nhs-england.gov
Commercial Director	+44 •••• ••••••	••••••••@nhs-england.gov
Procurement Manager	+44 •••• ••••••	••••••••@nhs-england.gov
Category Lead	+44 •••• ••••••	••••••••@nhs-england.gov
Senior Buyer	+44 •••• ••••••	••••••••@nhs-england.gov
Contracts Manager	+44 •••• ••••••	••••••••@nhs-england.gov